In vitro analysis of platelet concentrates stored in the presence of modulators of 3',5' adenosine monophosphate, and organic anions.
The storage of conventional platelet concentrates (PCs) under standard blood bank conditions is limited to five days, in part because longer storage periods lead to increasing damage in platelet integrity and functionality. The growing demand of PCs for clinical use, raises the interest to develop agents that would potentially permit a more extended period of storage. We have evaluated and compared the in vitro quality of PCs treated with: (1) Modulators of levels of cAMP (PGE1, foskolin, theophylline and isobutyl-methyl-xanthine [IBMX]); and (2) organic anions that function as alternative substrates of platelets (pyruvate and acetate). Platelet rich plasma (PRP) from pools (n = 6) of PCs was distributed into storage bags, and the agents to be tested were added, using saline as a control substance. PCs were stored at 22 degrees C with continuous agitation for up to 10 days. At 0, 5 and 10 days of storage, samples were analyzed for platelet counts, mean platelet volume (MPV), metabolic markers, and expression of glycoproteins (GPs). The addition of modulators of levels of cAMP, at the concentration used in the study, did not lead to substantial improvement in the parameters being evaluated, with respect to those in control units. The supplementation with organic anions, while not affecting the surface levels of GPs, favored the maintenance of metabolic values, such as pH, PCO2, and bicarbonate concentrations, as well as the preservation of MPV (p values < 0.05 respect to control units both at 5 and 10 days of storage). Our results indicate that while the use of modulators of levels of cAMP do not provide substantial benefit in the prevention of platelet storage lesions, organic anions have some advantageous effect in the storage promoted metabolic changes of PCs. These data might be considered when designing strategies to improve PC storage.
Lozano
M L
ML
Unit of Oncohematology and Hemotherapy, University General Hospital, School of Medicine, Murcia, Spain.
Rivera
J
J
Bermejo
E
E
Corral
J
J
Pérez
E
E
Vicente
V
V
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D019342:Acetic Acid / Q000494:pharmacology; D000527:Alprostadil / Q000494:pharmacology; D015703:Antigens, CD / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D001793:Blood Preservation; D002245:Carbon Dioxide / Q000097:blood; D002452:Cell Count; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000097:blood* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007770:L-Lactate Dehydrogenase; D019007:P-Selectin / Q000097:blood / Q000187:drug effects; D015539:Platelet Activation / Q000187:drug effects / Q000276:immunology; D010976:Platelet Count / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019038:Platelet Glycoprotein GPIb-IX Complex; D010980:Platelet Membrane Glycoproteins / Q000187:drug effects; D019289:Pyruvic Acid / Q000494:pharmacology; D017693:Sodium Bicarbonate / Q000097:blood; D060149:Tetraspanin 30; D013806:Theophylline / Q000494:pharmacology; D013997:Time Factors
D015703:Antigens, CD; C554586:CD63 protein, human; D019007:P-Selectin; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019038:Platelet Glycoprotein GPIb-IX Complex; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30; D002245:Carbon Dioxide; D005576:Colforsin; D019289:Pyruvic Acid; D017693:Sodium Bicarbonate; D013806:Theophylline; D000242:Cyclic AMP; D007770:L-Lactate Dehydrogenase; D000527:Alprostadil; D019342:Acetic Acid; D015056:1-Methyl-3-isobutylxanthine